Câncer de tireoide

Haugen BR, Alexander EK, Bible KC, et al; American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2016 Jan;26(1):1-133.Texto completo  Resumo

Wells SA Jr, Asa SL, Dralle H, et al. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid. 2015 Jun;25(6):567-610.Texto completo  Resumo

Gharib H, Papini E, Garber JR, et al. American Association of Clinical Endocrinologists, American College of Endocrinology, and Associazione Medici Endocrinologi medical guidelines for clinical practice for the diagnosis and management of thyroid nodules - 2016 update. Endocr Pract. 2016 May;22(5):622-39.Texto completo  Resumo

National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: thyroid carcinoma [internet publication].Texto completo

European Society for Medical Oncology. Clinical practice guidelines - thyroid cancer. 2019 [internet publication].Texto completo

1. Haugen BR, Alexander EK, Bible KC, et al; American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2016 Jan;26(1):1-133.Texto completo  Resumo

2. Kure S, Ohashi R. Thyroid Hürthle cell carcinoma: clinical, pathological, and molecular features. Cancers (Basel). 2020 Dec 23;13(1):26.Texto completo  Resumo

3. Jannin A, Escande A, Al Ghuzlan A, et al. Anaplastic thyroid carcinoma: an update. Cancers (Basel). 2022 Feb 19;14(4):1061.Texto completo  Resumo

4. Wells SA Jr, Asa SL, Dralle H, et al. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid. 2015 Jun;25(6):567-610.Texto completo  Resumo

5. Stein SA, Wartofsky L. Primary thyroid lymphoma: a clinical review. J Clin Endocrinol Metab. 2013 Aug;98(8):3131-8.Texto completo  Resumo

6. Walsh S, Lowery AJ, Evoy D, et al. Thyroid lymphoma: recent advances in diagnosis and optimal management strategies. Oncologist. 2013;18(9):994-1003.Texto completo  Resumo

7. Jung CK, Bychkov A, Kakudo K. Update from the 2022 World Health Organization classification of thyroid tumors: a standardized diagnostic approach. Endocrinol Metab (Seoul). 2022 Oct;37(5):703-18.Texto completo  Resumo

8. Ali SZ, Baloch ZW, Cochand-Priollet B, et al. The 2023 Bethesda system for reporting thyroid cytopathology. Thyroid. 2023 Sep;33(9):1039-44.Texto completo  Resumo

9. Amin MB, Edge S, Green F, et al, eds. AJCC cancer staging manual. 8th ed. (2017). Cham, Switzerland: Springer International; 2017.

10. Brierley JD, Gospodarowicz MK, Wittekind C, eds; Union for International Cancer Control. TNM classification of malignant tumors. 8th ed. Chichester, UK: Wiley-Blackwell; 2017.

11. Tessler FN, Middleton WD, Grant EG, et al. ACR thyroid imaging, reporting and data system (TI-RADS): white paper of the ACR TI-RADS Committee. J Am Coll Radiol. 2017 May;14(5):587-95.Texto completo  Resumo

12. Bertagna F, Treglia G, Piccardo A, et al. Diagnostic and clinical significance of F-18-FDG-PET/CT thyroid incidentalomas. J Clin Endocrinol Metab. 2012 Nov;97(11):3866-75.Texto completo  Resumo

13. Bible KC, Kebebew E, Brierley J, et al. 2021 American Thyroid Association guidelines for management of patients with anaplastic thyroid cancer. Thyroid. 2021 Mar;31(3):337-86.Texto completo  Resumo

14. Cabanillas ME, McFadden DG, Durante C. Thyroid cancer. Lancet. 2016 Dec 3;388(10061):2783-95. Resumo

15. Phillips JS, Pledger DR, Hilger AW. Rapid thyrotoxicosis in anaplastic thyroid carcinoma. J Laryngol Otol. 2007 Jul;121(7):695-7. Resumo

16. Pizzato M, Li M, Vignat J, et al. The epidemiological landscape of thyroid cancer worldwide: GLOBOCAN estimates for incidence and mortality rates in 2020. Lancet Diabetes Endocrinol. 2022 Apr;10(4):264-72. Resumo

17. National Cancer Institute. Surveillance, Epidemiology, and End Results (SEER) Program. Cancer stat facts: thyroid cancer. 2023 [internet publication].Texto completo

18. Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2022. CA Cancer J Clin. 2022 Jan;72(1):7-33.Texto completo  Resumo

19. James BC, Mitchell JM, Jeon HD, et al. An update in international trends in incidence rates of thyroid cancer, 1973-2007. Cancer Causes Control. 2018 May;29(4-5):465-73. Resumo

20. Panato C, Vaccarella S, Dal Maso L, et al. Thyroid cancer incidence in India between 2006 and 2014 and impact of overdiagnosis. J Clin Endocrinol Metab. 2020 Aug 1;105(8):2507-14.Texto completo  Resumo

21. Wu J, Zhao X, Sun J, et al. The epidemic of thyroid cancer in China: current trends and future prediction. Front Oncol. 2022 Sep 2;12:932729.Texto completo  Resumo

22. Miranda-Filho A, Lortet-Tieulent J, Bray F, et al. Thyroid cancer incidence trends by histology in 25 countries: a population-based study. Lancet Diabetes Endocrinol. 2021 Apr;9(4):225-34. Resumo

23. Wang C, Wu Z, Lei L, et al. Geographic disparities in trends of thyroid cancer incidence and mortality from 1990 to 2019 and a projection to 2030 across income-classified countries and territories. J Glob Health. 2023 Sep 29;13:04108.Texto completo  Resumo

24. Roman BR, Morris LG, Davies L. The thyroid cancer epidemic, 2017 perspective. Curr Opin Endocrinol Diabetes Obes. 2017 Oct;24(5):332-6.Texto completo  Resumo

25. Genere N, El Kawkgi OM, Giblon RE, et al. Incidence of clinically relevant thyroid cancers remains stable for almost a century: a population-based study. Mayo Clin Proc. 2021 Nov;96(11):2823-30.Texto completo  Resumo

26. Menicali E, Guzzetti M, Morelli S, et al. Immune landscape of thyroid cancers: new insights. Front Endocrinol (Lausanne). 2021 Apr 27;11:637826.Texto completo  Resumo

27. Fagin JA, Wells SA Jr. Biologic and clinical perspectives on thyroid cancer. N Engl J Med. 2016 Sep 15;375(11):1054-67.Texto completo  Resumo

28. Prete A, Borges de Souza P, Censi S, et al. Update on fundamental mechanisms of thyroid cancer. Front Endocrinol (Lausanne). 2020 Mar 13;11:102.Texto completo  Resumo

29. Gharib H, Papini E, Garber JR, et al. American Association of Clinical Endocrinologists, American College of Endocrinology, and Associazione Medici Endocrinologi medical guidelines for clinical practice for the diagnosis and management of thyroid nodules - 2016 update. Endocr Pract. 2016 May;22(5):622-39.Texto completo  Resumo

30. Singh Ospina N, Iñiguez-Ariza NM, Castro MR. Thyroid nodules: diagnostic evaluation based on thyroid cancer risk assessment. BMJ. 2020 Jan 7;368:l6670. Resumo

31. Grani G, Lamartina L, Durante C, et al. Follicular thyroid cancer and Hürthle cell carcinoma: challenges in diagnosis, treatment, and clinical management. Lancet Diabetes Endocrinol. 2018 Jun;6(6):500-14. Resumo

32. Williams D. Thyroid growth and cancer. Eur Thyroid J. 2015 Sep;4(3):164-73.Texto completo  Resumo

33. Fugazzola L, Elisei R, Fuhrer D, et al. 2019 European Thyroid Association guidelines for the treatment and follow-up of advanced radioiodine-refractory thyroid cancer. Eur Thyroid J. 2019 Oct;8(5):227-45.Texto completo  Resumo

34. Liu J, Liu Y, Lin Y, et al. Radioactive iodine-refractory differentiated thyroid cancer and redifferentiation therapy. Endocrinol Metab (Seoul). 2019 Sep;34(3):215-25.Texto completo  Resumo

35. Ciampi R, Romei C, Ramone T, et al. Genetic landscape of somatic mutations in a large cohort of sporadic medullary thyroid carcinomas studied by next-generation targeted sequencing. iScience. 2019 Oct 25;20:324-36.Texto completo  Resumo

36. Drozd V, Saenko V, Branovan DI, et al. A search for causes of rising incidence of differentiated thyroid cancer in children and adolescents after Chernobyl and Fukushima: comparison of the clinical features and their relevance for treatment and prognosis. Int J Environ Res Public Health. 2021 Mar 26;18(7):3444.Texto completo  Resumo

37. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: thyroid carcinoma [internet publication].Texto completo

38. Calcaterra V, Mameli C, Rossi V, et al. The iodine rush: over- or under-iodination risk in the prophylactic use of iodine for thyroid blocking in the event of a nuclear disaster. Front Endocrinol (Lausanne). 2022 May 26;13:901620.Texto completo  Resumo

39. de Leijer JF, Metman MJH, van der Hoorn A, et al. Focal thyroid incidentalomas on (18)F-FDG PET/CT: a systematic review and meta-analysis on prevalence, risk of malignancy and inconclusive fine needle aspiration. Front Endocrinol (Lausanne). 2021;12:723394.Texto completo  Resumo

40. American College of Radiology. ACR-AIUM-SPR-SRU practice parameter for the performance and interpretation of diagnostic ultrasound of the extracranial head and neck. 2022 [internet publication].Texto completo

41. American College of Radiology. ACR appropriateness criteria: thyroid disease​. 2019 [internet publication].Texto completo

42. Zhao H, Li H. Meta-analysis of ultrasound for cervical lymph nodes in papillary thyroid cancer: diagnosis of central and lateral compartment nodal metastases. Eur J Radiol. 2019 Mar;112:14-21. Resumo

43. Hoang JK, Middleton WD, Tessler FN. Update on ACR TI-RADS: successes, challenges, and future directions, from the AJR Special Series on Radiology Reporting and Data Systems. AJR Am J Roentgenol. 2021 Mar;216(3):570-8.Texto completo  Resumo

44. Russ G, Bonnema SJ, Erdogan MF, et al. European Thyroid Association Guidelines for ultrasound malignancy risk stratification of thyroid nodules in adults: the EU-TIRADS. Eur Thyroid J. 2017 Sep;6(5):225-37.Texto completo  Resumo

45. Rossi ED, Pantanowitz L, Faquin WC. The role of molecular testing for the indeterminate thyroid FNA. Genes (Basel). 2019 Sep 23;10(10):736.Texto completo  Resumo

46. Filetti S, Durante C, Hartl DM, et al. ESMO clinical practice guideline update on the use of systemic therapy in advanced thyroid cancer. Ann Oncol. 2022 Jul;33(7):674-84.Texto completo  Resumo

47. Ahn HS, Kim HS, Hong MJ. Ultrasonographic and cytologic assessments of follicular neoplasms of the thyroid: predictive features differentiating follicular carcinoma from follicular adenoma. PLoS One. 2022 Jul 21;17(7):e0271437.Texto completo  Resumo

48. McHenry CR, Phitayakorn R. Follicular adenoma and carcinoma of the thyroid gland. Oncologist. 2011;16(5):585-93.Texto completo  Resumo

49. Cibas ES, Ali SZ. The 2017 Bethesda system for reporting thyroid cytopathology. Thyroid. 2017 Nov;27(11):1341-6.Texto completo  Resumo

50. Zhang L, Castellana M, Virili C, et al. Fine-needle aspiration to diagnose primary thyroid lymphomas: a systematic review and meta-analysis. Eur J Endocrinol. 2019 Mar;180(3):177-87.Texto completo  Resumo

51. Novoa E, Gürtler N, Arnoux A, et al. Role of ultrasound-guided core-needle biopsy in the assessment of head and neck lesions: a meta-analysis and systematic review of the literature. Head Neck. 2012 Oct;34(10):1497-503. Resumo

52. Durante C, Hegedüs L, Czarniecka A, et al. 2023 European Thyroid Association clinical practice guidelines for thyroid nodule management. Eur Thyroid J. 2023 Oct 1;12(5):e230067.Texto completo  Resumo

53. Viola D, Elisei R. Management of medullary thyroid cancer. Endocrinol Metab Clin North Am. 2019 Mar;48(1):285-301. Resumo

54. Webb RC, Howard RS, Stojadinovic A, et al. The utility of serum thyroglobulin measurement at the time of remnant ablation for predicting disease-free status in patients with differentiated thyroid cancer: a meta-analysis involving 3947 patients. J Clin Endocrinol Metab. 2012 Aug;97(8):2754-63.Texto completo  Resumo

55. National Institute for Health and Care Excellence. Thyroid disease: assessment and management. Oct 2023 [internet publication].Texto completo

56. Samarasinghe S, Meah F, Singh V, et al. Biotin interference with routine clinical immunoassays: understand the causes and mitigate the risks. Endocr Pract. 2017 Aug;23(8):989-98. Resumo

57. Li D, Ferguson A, Cervinski MA, et al. AACC guidance document on biotin interference in laboratory tests. J Appl Lab Med. 2020 May 1;5(3):575-87.Texto completo  Resumo

58. Li W, Song Q, Lan Y, et al. The value of sonography in distinguishing follicular thyroid carcinoma from adenoma. Cancer Manag Res. 2021 May 17:13:3991-4002.Texto completo  Resumo

59. National Institute for Health and Care Excellence. Thyroid cancer: assessment and management. Dec 2022 [internet publication].Texto completo

60. Patel KN, Yip L, Lubitz CC, et al. The American Association of Endocrine Surgeons guidelines for the definitive surgical management of thyroid disease in adults. Ann Surg. 2020 Mar;271(3):e21-93. Resumo

61. Garau LM, Rubello D, Muccioli S, et al. The sentinel lymph node biopsy technique in papillary thyroid carcinoma: the issue of false-negative findings. Eur J Surg Oncol. 2020 Jun;46(6):967-75. Resumo

62. Garau LM, Rubello D, Morganti R, et al. Sentinel lymph node biopsy in small papillary thyroid cancer: a meta-analysis. Clin Nucl Med. 2019 Feb;44(2):107-18. Resumo

63. Albers MB, Nordenström E, Wohlfahrt J, et al. Sentinel lymph node biopsy in thyroid cancer. World J Surg. 2020 Jan;44(1):142-7. Resumo

64. Perrier ND, Brierley JD, Tuttle RM. Differentiated and anaplastic thyroid carcinoma: major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin. 2018 Jan;68(1):55-63.Texto completo  Resumo

65. Momesso DP, Tuttle RM. Update on differentiated thyroid cancer staging. Endocrinol Metab Clin North Am. 2014 Jun;43(2):401-21. Resumo

66. Tuttle RM, Alzahrani AS. Risk stratification in differentiated thyroid cancer: from detection to final follow-up. J Clin Endocrinol Metab. 2019 Mar 15;104(9):4087-100.Texto completo  Resumo

67. US Preventive Services Task Force. Screening for thyroid cancer: US Preventive Services Task Force recommendation statement. JAMA. 2017 May 9;317(18):1882-7.Texto completo  Resumo

68. Perros P, Boelaert K, Colley S, et al; British Thyroid Association. Guidelines for the management of thyroid cancer. Clin Endocrinol (Oxf). 2014;81 Suppl 1:1-122.Texto completo  Resumo

69. European Society for Medical Oncology. Clinical practice guidelines - thyroid cancer. 2019 [internet publication].Texto completo

70. Saravana-Bawan B, Bajwa A, Paterson J, et al. Active surveillance of low-risk papillary thyroid cancer: a meta-analysis. Surgery. 2020 Jan;167(1):46-55. Resumo

71. Ito Y, Miyauchi A, Oda H. Low-risk papillary microcarcinoma of the thyroid: a review of active surveillance trials. Eur J Surg Oncol. 2018 Mar;44(3):307-15.Texto completo  Resumo

72. Biondi B, Cooper DS. Thyroid hormone suppression therapy. Endocrinol Metab Clin North Am. 2019 Mar;48(1):227-37. Resumo

73. Brancatella A, Marcocci C. TSH suppressive therapy and bone. Endocr Connect. 2020 Jul;9(7):R158-72.Texto completo  Resumo

74. Chen L, Wu YH, Lee CH, et al. Prophylactic central neck dissection for papillary thyroid carcinoma with clinically uninvolved central neck lymph nodes: a systematic review and meta-analysis. World J Surg. 2018 Sep;42(9):2846-57. Resumo

75. Tuttle RM, Ahuja S, Avram AM, et al. Controversies, consensus, and collaboration in the use of (131)I therapy in differentiated thyroid cancer: a joint statement from the American Thyroid Association, the European Association of Nuclear Medicine, the Society of Nuclear Medicine and Molecular Imaging, and the European Thyroid Association. Thyroid. 2019 Apr;29(4):461-70.Texto completo  Resumo

76. Pacini F, Fuhrer D, Elisei R, et al. 2022 ETA consensus statement: what are the indications for post-surgical radioiodine therapy in differentiated thyroid cancer? Eur Thyroid J. 2022 Jan 1;11(1):e210046.Texto completo  Resumo

77. Leboulleux S, Bournaud C, Chougnet CN, et al. Thyroidectomy without radioiodine in patients with low-risk thyroid cancer. N Engl J Med. 2022 Mar 10;386(10):923-32.Texto completo  Resumo

78. Gulec SA, Ahuja S, Avram AM, et al. A joint statement from the American Thyroid Association, the European Association of Nuclear Medicine, the European Thyroid Association, the Society of Nuclear Medicine and Molecular Imaging on current diagnostic and theranostic approaches in the management of thyroid cancer. Thyroid. 2021 Jul;31(7):1009-19.Texto completo  Resumo

79. Scharpf J, Tuttle M, Wong R, et al. Comprehensive management of recurrent thyroid cancer: an American Head and Neck Society consensus statement. Head Neck. 2016 Dec;38(12):1862-9.Texto completo  Resumo

80. Tumino D, Frasca F, Newbold K. Updates on the management of advanced, metastatic, and radioiodine refractory differentiated thyroid cancer. Front Endocrinol (Lausanne). 2017 Nov 20;8:312.Texto completo  Resumo

81. Verburg FA, Hänscheid H, Luster M. Radioactive iodine (RAI) therapy for metastatic differentiated thyroid cancer. Best Pract Res Clin Endocrinol Metab. 2017 Jun;31(3):279-90. Resumo

82. Shonka DC Jr, Ho A, Chintakuntlawar AV, et al. American Head and Neck Society Endocrine Surgery Section and International Thyroid Oncology Group consensus statement on mutational testing in thyroid cancer: defining advanced thyroid cancer and its targeted treatment. Head Neck. 2022 Jun;44(6):1277-300. Resumo

83. Rao SN, Smallridge RC. Anaplastic thyroid cancer: an update. Best Pract Res Clin Endocrinol Metab. 2022 May 27;101678. Resumo

84. Maniakas A, Zafereo M, Cabanillas ME. Anaplastic thyroid cancer: new horizons and challenges. Endocrinol Metab Clin North Am. 2022 Jun;51(2):391-401. Resumo

85. Wang JR, Zafereo ME, Dadu R, et al. Complete surgical resection following neoadjuvant dabrafenib plus trametinib in BRAF(V600E)-mutated anaplastic thyroid carcinoma. Thyroid. 2019 Aug;29(8):1036-43.Texto completo  Resumo

86. Hadoux J, Pacini F, Tuttle RM, et al. Management of advanced medullary thyroid cancer. Lancet Diabetes Endocrinol. 2016 Jan;4(1):64-71. Resumo

87. Leboulleux S, Do Cao C, Zerdoud S, et al. A phase II redifferentiation trial with dabrafenib-trametinib and 131I in metastatic radioactive iodine refractory BRAF p.V600E-mutated differentiated thyroid cancer. Clin Cancer Res. 2023 Jul 5;29(13):2401-9.Texto completo  Resumo

88. American Cancer Society. Thyroid cancer survival rates, by type and stage. 2022 [internet publication].Texto completo

89. Maniakas A, Dadu R, Busaidy NL, et al. Evaluation of overall survival in patients with anaplastic thyroid carcinoma, 2000-2019. JAMA Oncol. 2020 Sep 1;6(9):1397-404.Texto completo  Resumo

90. Biondi B, Cooper DS. Subclinical hyperthyroidism. N Engl J Med. 2018 Jun 21;378(25):2411-9. Resumo

91. Molenaar RJ, Sidana S, Radivoyevitch T, et al. Risk of hematologic malignancies after radioiodine treatment of well-differentiated thyroid cancer. J Clin Oncol. 2018 Jun 20;36(18):1831-9.Texto completo  Resumo

92. Iyer NG, Morris LG, Tuttle RM, et al. Rising incidence of second cancers in patients with low-risk (T1N0) thyroid cancer who receive radioactive iodine therapy. Cancer. 2011 Oct 1;117(19):4439-46.Texto completo  Resumo

93. Sugitani I, Fujimoto Y. Effect of postoperative thyrotropin suppressive therapy on bone mineral density in patients with papillary thyroid carcinoma: a prospective controlled study. Surgery. 2011 Dec;150(6):1250-7. Resumo

94. Qi L, Zhang W, Ren X, et al. Incidence and predictors of synchronous bone metastasis in newly diagnosed differentiated thyroid cancer: a real-world population-based study. Front Surg. 2022;9:778303.Texto completo  Resumo

95. Royal College of Physicians (UK). Evidence-based indications for the use of PET-CT in the UK 2016. May 2016 [internet publication].Texto completo

96. Sisson JC, Freitas J, McDougall IR, et al; American Thyroid Association Taskforce On Radioiodine Safety. Radiation safety in the treatment of patients with thyroid diseases by radioiodine 131I: practice recommendations of the American Thyroid Association. Thyroid. 2011 Apr;21(4):335-46.Texto completo  Resumo